1. |
Therapeutic angiogenesis shows promise but questions remain |
|
Inpharma Weekly,
Volume &NA;,
Issue 1143,
1998,
Page 2-2
&NA;,
Preview
|
PDF (842KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
2. |
Preventing neonatal GBS infectionare guidelines appropriate? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1143,
1998,
Page 3-3
&NA;,
Preview
|
PDF (746KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
3. |
Guidelines for treating CMV diseases in patients with AIDS |
|
Inpharma Weekly,
Volume &NA;,
Issue 1143,
1998,
Page 4-4
&NA;,
Preview
|
PDF (788KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
4. |
Terbinafine superior to itraconazole in onychomycosis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1143,
1998,
Page 5-5
&NA;,
Preview
|
PDF (712KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
5. |
Paclitaxel prepares for first-line in advanced ovarian cancer |
|
Inpharma Weekly,
Volume &NA;,
Issue 1143,
1998,
Page 6-7
Mark Greener,
Preview
|
PDF (1560KB)
|
|
摘要:
Paclitaxel [‘Taxol’] plus a platinum compound emerged as a contender for first-line treatment of ovarian cancer in a study presented during the 34th Annual Meeting of the American Society of Clinical Oncology (ASCO) [Los Angeles, US; May 1998]. Indeed, the evidence is now so convincing that leading UK ovarian cancer specialists drew up guidelines suggesting that all women with advanced ovarian cancer should have access to paclitaxel. Currently, not all UK health authorities fund this drug. Meanwhile, other studies presented during the meeting highlighted the role of adverse effects as cost drivers in cancer care.
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
6. |
Imperfect HIV vaccines could still be cost effective |
|
Inpharma Weekly,
Volume &NA;,
Issue 1143,
1998,
Page 7-7
&NA;,
Preview
|
PDF (769KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
7. |
ISIS-2302 promising in Crohn's disease |
|
Inpharma Weekly,
Volume &NA;,
Issue 1143,
1998,
Page 8-8
&NA;,
Preview
|
PDF (737KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
8. |
Expanding horizons for endothelin-receptor antagonists |
|
Inpharma Weekly,
Volume &NA;,
Issue 1143,
1998,
Page 9-10
Wayne Elwood,
Preview
|
PDF (1509KB)
|
|
摘要:
Rapid development of endothelin (ET)-receptor antagonists by the pharmaceutical industry reflects the potential therapeutic significance of these agents. The primary therapeutic indication for ET-receptor antagonists has been congestive heart failure, and recent clinical data support a role for these novel agents in the treatment of this indication.*However, development of potent and selective endothelin antagonists has helped in the identification of other diseases in which this peptide may also play an important role. Pulmonary hypertension and perhaps asthma are leading contenders in the list of diseases likely to benefit from clinically effective, orally active ET-receptor antagonists, delegates were told at the International Conference of the American Lung Association and the American Thoracic Society [Chicago, US; April 1998].
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
9. |
IgG avidity for polysaccharides distinguishes vaccines |
|
Inpharma Weekly,
Volume &NA;,
Issue 1143,
1998,
Page 10-10
&NA;,
Preview
|
PDF (748KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
10. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1143,
1998,
Page 11-11
&NA;,
Preview
|
PDF (769KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|